Ivonescimab's HARMONi OS Update Sharpens the U.S. Approval Plot

Western patients now match Asian survival benefit; Summit adds Arcus combo and preps for Nov. 14 PDUFA.

SMMT · Earnings Call · 2026-07-23

HARMONi's Western convergence

Summit Therapeutics reported a quiet-but-loaded Q2: no new Phase III headline, but the company served the data that regulators and investors have been waiting for. The updated overall survival analysis from the global HARMONi trial in EGFR-mutated non-small cell lung cancer showed a hazard ratio of 0.76 in both the total population and, crucially, in Western patients now followed a median of 23 months. That is the first time the regional data have converged with Asia.“Western patients increased their time on study, reaching a median follow-up of over 23 months.” — Mahkam Zanganeh, Executive or Senior Management · 2026-07-23 The prior call, in February 2026, leaned on the same theme but from a shallower dataset: Dave Gancarz had stressed the importance of follow-up time to convince regulators of translatability.

All of the readouts that we've seen to date have pointed in one direction, which has been highly encouraging.
Dave Gancarz, Chief Financial Officer · 2026-02-24

Now the Western patients curve has matured, and the survival gap versus Asian patients has essentially disappeared, a point management repeated on the call. This shift matters commercially as much as clinically. The November 14 PDUFA date is approaching, and the FDA has said it would need a statistically significant OS benefit for approval in this setting. The updated analysis, with a nominal p-level below significance, may not convert to statistical significance, but it strengthens the totality-of-evidence argument and, for the first time, demonstrates that the drug's survival benefit is not a China-only phenomenon. As Dave Gancarz put it, the takeaway is that "maturity and follow-up time is critical, in particular, for ivonescimab as a next-generation immunotherapy."“The takeaway... is that maturity and follow-up time is critical, in particular, for ivonescimab as a next-generation immunotherapy.” — Dave Gancarz, Chief Financial Officer · 2026-07-23

HARMONi-3's next look: alpha, timing, and the elephant in the room

The company also refined the upcoming HARMONi-3 readout map. The squamous PFS analysis is expected in H2 2026, with an accompanying interim OS look, and a second, fully-powered interim OS look in H1 2027. Management was careful to frame the alpha-spend implications: the PFS-tied OS look is minimal, leaving two full shots at OS later.“We still expect to reach the number of events needed for the PFS analysis in the second half of this year. But that timing is not next month...” — Dave Gancarz, Chief Financial Officer · 2026-07-23 Analysts pressed on whether the earlier, missed interim PFS (conducted but not disclosed) signals a weaker signal. Dave deferred, noting the analysis was performed by the DMC and remains blinded, but the market has likely priced in some uncertainty. The repeated emphasis on look at OS and the formal definition of alpha spend underscores how much of the story now hinges on survival maturity rather than PFS alone.

Commercial ramp and a new Arcus collaboration

Cash is the fuel. Summit ended Q2 with $690.7 million, raised $231 million from its ATM, and filed a new $380 million ATM to extend the runway. But that runway is not infinite: research and development expense rose 159% y/y to $133 million as HARMONi-GI3 and the two frontline lung studies accelerate. Management is spending in anticipation of a launch, having already hired commercial leadership and MSLs. The company also announced a fresh collaboration with Arcus to test ivonescimab with casdatifan, a HIF-2α inhibitor, in renal cell carcinoma—another signal that ivonescimab is becoming the backbone for novel combos, following the RevMed and GSK deals. Arcus is the latest partner to validate the platform. Yet the stock is down ~33% over the past 90 days, reflecting the high cash burn, dilution, and the lingering question of whether HARMONi-3 will truly deliver the survival separation that HARMONi now hints at. The stage is set for a binary fall.